Gilead's Descovy HIV Prevention Indication Should Exclude Women, US FDA Advisory Cmte. Says

 
• By Sue Sutter

Gilead and the FDA failed women by letting PrEP application get this far without clinical efficacy data in non-transgendered females, panel members say in close vote against a broad indication; panelists urge the agency to mandate such studies regardless of the breadth of the HIV pre-exposure prophylaxis indication ultimately granted to the Truvada successor.

FDA Advisory Committee Feature image
An FDA AdComm majority supported a narrow PrEP indication for Descovy.

More from US FDA Performance Tracker

More from Regulatory Trackers